• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Antiplatelet drugs provide first-line antithrombotic therapy for the management of acute
ischemic syndromes (both coronary and cerebrovascular) and for the prevention of their …

Background Current guidelines recommend potent platelet inhibition with prasugrel or
ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous …

Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …

Platelets play a fundamental role in normal hemostasis, while their inherited or acquired
dysfunctions are involved in a variety of bleeding disorders or thrombotic events. Several …

Platelet ACKR3/CXCR7 surface expression is enhanced and influences prognosis in
coronary artery disease (CAD) patients, who exhibit a distinct atherothrombotic platelet …

Introduction: Variability in individual response profiles to antiplatelet therapy, in particular
clopidogrel, is a well-established phenomenon. Genetic variations of the cytochrome P450 …

Aims Guided de-escalation of P2Y12-inhibitor treatment was recently identified as an
effective alternative treatment strategy in acute coronary syndrome (ACS) patients …

Objectives: This study sought to evaluate the impact of initial platelet reactivity on the benefit
of switched strategy. Background: TOPIC (Timing Of Platelet Inhibition after acute Coronary …

Aims In patients undergoing percutaneous coronary intervention (PCI) for acute myocardial
infarction (AMI), the risk of ischaemic complications is highest in the early phase (during the …